Senti Biosciences Holdings Inc SNTI
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $0.46
- Day Range
- $0.42–0.46
- 52-Week Range
- $0.42–2.88
- Bid/Ask
- $0.43 / $0.44
- Shares Outstanding
- 31.14M
- Market Cap
- $13.61M
- Volume/Avg
- 11,530 / 265,753
Key Statistics
- Price/Earnings (Normalized)
- 0.07
- Price/Sales
- 318.75
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Senti Biosciences Holdings Inc, formerly known as Senti Biosciences Inc, is a clinical-stage biotechnology company developing cell and gene therapies using its gene circuit platform for patients with incurable diseases. Its gene circuits, created from proprietary DNA sequences, are designed to reprogram cells to sense, compute, and respond to cellular environments. Its product candidates are to kill cancer cells, spare healthy cells, increase specificity, and control drug expression. Its candidate, SENTI-202, is a logic-gated off-the-shelf CAR-NK cell therapy for blood cancers, currently in a Phase 1 clinical trial in the United States and Australia for relapsed or refractory hematological malignancies, including Acute Myeloid Leukemia (AML).
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 39
- Website
- https://www.sentibio.com
Valuation
|
Metric
|
SNTI
|
|---|---|
Price/Earnings (Normalized) | 0.07 |
Price/Book Value | 5.31 |
Price/Sales | 318.75 |
Price/Cash Flow | — |
Price/Earnings
SNTI
Financial Strength
|
Metric
|
SNTI
|
|---|---|
Quick Ratio | 0.68 |
Current Ratio | 1.04 |
Interest Coverage | — |
Quick Ratio
SNTI
Profitability
|
Metric
|
SNTI
|
|---|---|
Return on Assets (Normalized) | −81.03% |
Return on Equity (Normalized) | −301.83% |
Return on Invested Capital (Normalized) | −109.19% |
Return on Assets
SNTI
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|#m@#hFQ | LOCK|F&Jnc | $123B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|>yQ%Srr | LOCK|<#@h | $71B | |||
| argenx SE ADR
ARGX
| LOCK|?H&<KY | LOCK|^j | $54B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|VQGJsvV | LOCK|#hZ | $36B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|t?C#&>X | LOCK|#xlt$ | $36B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|L^?@p<<$ | LOCK|dbS>^ | $26B | |||
| Moderna Inc
MRNA
| LOCK|%qZ<nrD | LOCK|BLj | $25B | |||
| Incyte Corp
INCY
| LOCK|CgLsvzB | LOCK|!VB | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|D$lZ^Lj | LOCK|Sg^ | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|Gmsf?^% | LOCK|c# | $16B |
United States